Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

Intensive treatment strategies in advanced-stage Hodgkin's lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials.

von Tresckow B, Kreissl S, Goergen H, Bröckelmann PJ, Pabst T, Fridrik M, Rummel M, Jung W, Thiemer J, Sasse S, Bürkle C, Baues C, Diehl V, Engert A, Borchmann P; German Hodgkin Study Group.

Lancet Haematol. 2018 Oct;5(10):e462-e473. doi: 10.1016/S2352-3026(18)30140-6.

PMID:
30290903
2.

ASCO update on lymphoma.

Fridrik MA.

Memo. 2017;10(4):218-219. doi: 10.1007/s12254-017-0372-y. Epub 2017 Nov 24. Review.

3.

A prospective, multicenter pilot study to investigate the feasibility and safety of a 1-year controlled exercise training after adjuvant chemotherapy in colorectal cancer patients.

Piringer G, Fridrik M, Fridrik A, Leiherer A, Zabernigg A, Greil R, Eisterer W, Tschmelitsch J, Lang A, Frantal S, Burgstaller S, Gnant M, Thaler J; Austrian Breast and Colorectal Cancer Study Group (ABCSG).

Support Care Cancer. 2018 Apr;26(4):1345-1352. doi: 10.1007/s00520-017-3961-8. Epub 2017 Nov 22.

PMID:
29168033
4.

Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients - AGMT_GASTRIC-3.

Wöll E, Thaler J, Keil F, Gruenberger B, Hejna M, Eisterer W, Fridrik MA, Ulmer H, Trommet V, Huemer F, Weiss L, Greil R.

Anticancer Res. 2017 Oct;37(10):5553-5558.

PMID:
28982869
5.

Torsade de pointes in a patient with severe hypercalcaemia and multiple myeloma.

Fuchs D, Voskova D, Krenosz KJ, Lambert T, Fridrik MA.

Neth J Med. 2017 Jun;75(5):208-210.

6.

Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial.

Greil R, Obrtlíková P, Smolej L, Kozák T, Steurer M, Andel J, Burgstaller S, Mikušková E, Gercheva L, Nösslinger T, Papajík T, Ladická M, Girschikofsky M, Hrubiško M, Jäger U, Fridrik M, Pecherstorfer M, Králiková E, Burcoveanu C, Spasov E, Petzer A, Mihaylov G, Raynov J, Oexle H, Zabernigg A, Flochová E, Palášthy S, Stehlíková O, Doubek M, Altenhofer P, Pleyer L, Melchardt T, Klingler A, Mayer J, Egle A.

Lancet Haematol. 2016 Jul;3(7):e317-29. doi: 10.1016/S2352-3026(16)30045-X. Epub 2016 Jun 16.

PMID:
27374465
8.

Erratum to: Iron metabolism and iron supplementation in cancer patients.

Ludwig H, Evstatiev R, Kornek G, Aapro M, Bauernhofer T, Buxhofer-Ausch V, Fridrik M, Geissler D, Geissler K, Gisslinger H, Koller E, Kopetzky G, Lang A, Rumpold H, Steurer M, Kamali H, Link H.

Wien Klin Wochenschr. 2015 Dec;127(23-24):920-1. doi: 10.1007/s00508-015-0893-5. No abstract available.

9.

Treatment of Patients With Myelodysplastic Syndrome With Lenalidomide in Clinical Routine in Austria.

Aschauer G, Greil R, Linkesch W, Nösslinger T, Stauder R, Burgstaller S, Fiegl M, Fridrik M, Girschikofsky M, Keil F, Petzer A.

Clin Lymphoma Myeloma Leuk. 2015 Nov;15(11):e143-9. doi: 10.1016/j.clml.2015.07.645. Epub 2015 Aug 5.

PMID:
26422252
10.

Iron metabolism and iron supplementation in cancer patients.

Ludwig H, Evstatiev R, Kornek G, Aapro M, Bauernhofer T, Buxhofer-Ausch V, Fridrik M, Geissler D, Geissler K, Gisslinger H, Koller E, Kopetzky G, Lang A, Rumpold H, Steurer M, Kamali H, Link H.

Wien Klin Wochenschr. 2015 Dec;127(23-24):907-19. doi: 10.1007/s00508-015-0842-3. Epub 2015 Sep 15. Review. Erratum in: Wien Klin Wochenschr. 2015 Dec;127(23-24):920-1.

11.

Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial.

Jaeger U, Trneny M, Melzer H, Praxmarer M, Nawarawong W, Ben Yehuda D, Goldstein D, Mihaljevic B, Ilhan O, Ballova V, Hedenus M, Hsiao LT, Au WY, Burgstaller S, Weidinger G, Keil F, Dittrich C, Skrabs C, Klingler A, Chott A, Fridrik MA, Greil R; AGMT-NHL13 Investigators.

Haematologica. 2015 Jul;100(7):955-63. doi: 10.3324/haematol.2015.125344. Epub 2015 Apr 24.

12.

Lapatinib-plus-pegylated liposomal doxorubicin in advanced HER2-positive breast cancer following trastuzumab: a phase II trial.

Pircher M, Mlineritsch B, Fridrik MA, Dittrich C, Lang A, Petru E, Weltermann A, Thaler J, Hufnagl C, Gampenrieder SP, Rinnerthaler G, Ressler S, Ulmer H, Greil R.

Anticancer Res. 2015 Jan;35(1):517-21.

PMID:
25550597
13.

A phase 1 dose escalation study of BI 831266, an inhibitor of Aurora kinase B, in patients with advanced solid tumors.

Dittrich C, Fridrik MA, Koenigsberg R, Lee C, Goeldner RG, Hilbert J, Greil R.

Invest New Drugs. 2015 Apr;33(2):409-22. doi: 10.1007/s10637-014-0201-7. Epub 2014 Dec 23.

14.
15.

Experience with lenalidomide in an Austrian non-study population with advanced myelofibrosis.

Burgstaller S, Fridrik M, Hojas S, Kühr T, Ludwig H, Mayrbäurl B, Pöhnl R, Pötscher M, Schlögl E, Zauner D, Thaler J, Gisslinger H.

Wien Klin Wochenschr. 2013 Apr;125(7-8):196-9. doi: 10.1007/s00508-013-0345-z. Epub 2013 Mar 28.

PMID:
23536018
16.

Rituximab plus subcutaneous cladribine in patients with extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: a phase II study by the Arbeitsgemeinschaft Medikamentose Tumortherapie.

Troch M, Kiesewetter B, Willenbacher W, Willenbacher E, Zebisch A, Linkesch W, Fridrik M, Müllauer L, Greil R, Raderer M.

Haematologica. 2013 Feb;98(2):264-8. doi: 10.3324/haematol.2012.072587. Epub 2012 Sep 14.

17.

Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response.

Jäger U, Fridrik M, Zeitlinger M, Heintel D, Hopfinger G, Burgstaller S, Mannhalter C, Oberaigner W, Porpaczy E, Skrabs C, Einberger C, Drach J, Raderer M, Gaiger A, Putman M, Greil R; Arbeitsgemeinschaft Medikamentöse Tumortherapie (AGMT) Investigators.

Haematologica. 2012 Sep;97(9):1431-8. Epub 2012 Apr 17.

18.

Prognostic value of number of removed lymph nodes, number of involved lymph nodes, and lymph node ratio in 7502 breast cancer patients enrolled onto trials of the Austrian Breast and Colorectal Cancer Study Group (ABCSG).

Tausch C, Taucher S, Dubsky P, Seifert M, Reitsamer R, Kwasny W, Jakesz R, Fitzal F, Filipcic L, Fridrik M, Greil R, Gnant M.

Ann Surg Oncol. 2012 Jun;19(6):1808-17. doi: 10.1245/s10434-011-2189-y. Epub 2011 Dec 30.

PMID:
22207051
19.

Oxaliplatin, irinotecan and cetuximab in advanced gastric cancer. A multicenter phase II trial (Gastric-2) of the Arbeitsgemeinschaft Medikamentose Tumortherapie (AGMT).

Wöll E, Greil R, Eisterer W, Bechter O, Fridrik MA, Grünberger B, Zabernigg A, Mayrbäurl B, Russ G, Dlaska M, Obrist P, Thaler J.

Anticancer Res. 2011 Dec;31(12):4439-43.

PMID:
22199312
20.

Sentinel node biopsy after primary chemotherapy in breast cancer: a note of caution from results of ABCSG-14.

Tausch C, Steger GG, Haid A, Jakesz R, Fridrik MA, Reitsamer R, Pöstlberger S, Lang A, Gnant M, Greil R.

Breast J. 2011 May-Jun;17(3):230-8. doi: 10.1111/j.1524-4741.2011.01073.x. Epub 2011 Mar 31.

PMID:
21450019
21.

First annual report of the Austrian CML registry.

Schmidt S, Wolf D, Thaler J, Burgstaller S, Linkesch W, Petzer A, Fridrik M, Lang A, Agis H, Valent P, Krieger O, Walder A, Korger M, Schlögl E, Sliwa T, Wöll E, Mitterer M, Eisterer W, Pober M, Gastl G; ASHO CML registry.

Wien Klin Wochenschr. 2010 Oct;122(19-20):558-66. doi: 10.1007/s00508-010-1450-x. Epub 2010 Oct 11.

PMID:
20936366
22.

Dose-dense therapy improves survival in aggressive non-Hodgkin's lymphoma.

Fridrik MA, Hausmaninger H, Lang A, Drach J, Krieger O, Geissler D, Michlmayr G, Ulsperger E, Chott A, Oberaigner W, Greil R.

Ann Hematol. 2010 Mar;89(3):273-82. doi: 10.1007/s00277-009-0811-x. Epub 2009 Aug 20.

PMID:
19693500
23.

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Pöstlberger S, Menzel C, Jakesz R, Seifert M, Hubalek M, Bjelic-Radisic V, Samonigg H, Tausch C, Eidtmann H, Steger G, Kwasny W, Dubsky P, Fridrik M, Fitzal F, Stierer M, Rücklinger E, Greil R; ABCSG-12 Trial Investigators, Marth C.

N Engl J Med. 2009 Feb 12;360(7):679-91. doi: 10.1056/NEJMoa0806285. Erratum in: N Engl J Med. 2009 May 28;360(22):2379.

24.

Multicenter phase II study of pegylated liposomal doxorubicin in combination with vinorelbine as first-line treatment in elderly patients with metastatic breast cancer.

Mlineritsch B, Schabel-Moser R, Andel J, Fridrik M, Moik M, Mayer P, Russ G, Rass C, Greil R; Arbeitsgemeinschaft medikamentöse Tumortherapie Study Group.

Onkologie. 2009 Feb;32(1-2):18-24. doi: 10.1159/000180915. Epub 2009 Jan 20.

PMID:
19209014
25.

[Malignant lymphoma in adults].

Fridrik MA.

Dtsch Med Wochenschr. 2008 Oct;133(41):2109-14. doi: 10.1055/s-0028-1091252. Epub 2008 Oct 1. Review. German. No abstract available.

PMID:
18985565
26.

Sentinel node mapping performed before preoperative chemotherapy may avoid axillary dissection in breast cancer patients with negative or micrometastatic sentinel nodes.

Schrenk P, Tausch C, Wölfl S, Bogner S, Fridrik M, Wayand W.

Am J Surg. 2008 Aug;196(2):176-83. doi: 10.1016/j.amjsurg.2007.08.068. Epub 2008 May 29.

PMID:
18513692
27.

Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy.

Dubsky P, Sevelda P, Jakesz R, Hausmaninger H, Samonigg H, Seifert M, Denison U, Mlineritsch B, Steger G, Kwasny W, Stöger H, Bartsch R, Stierer M, Taucher S, Fridrik M, Schippinger W, Greil R, Pötter R, Gnant M; Austrian Breast and Colorectal Cancer Study Group.

Clin Cancer Res. 2008 Apr 1;14(7):2082-7. doi: 10.1158/1078-0432.CCR-07-2068.

28.

Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17).

Mlineritsch B, Tausch C, Singer C, Luschin-Ebengreuth G, Jakesz R, Ploner F, Stierer M, Melbinger E, Menzel C, Urbania A, Fridrik M, Steger G, Wohlmuth P, Gnant M, Greil R; Austrian Breast, Colorectal Cancer Study Group (ABCSG).

Breast Cancer Res Treat. 2008 Nov;112(1):203-13. Epub 2007 Dec 22.

PMID:
18158620
29.

Is the statistical difference clinically relevant?

Fridrik MA.

J Clin Oncol. 2005 Nov 20;23(33):8537; author reply 8537-8. No abstract available.

PMID:
16293884
30.
31.

Long-term results of dose density therapy in patients with aggressive lymphoma.

Fridrik MA, Hausmaninger H, Linkesch W, Greil R, Krieger O, Baldinger C, Klocker J, Pont J, Oberaigner W.

Ann Hematol. 2005 Apr;84(4):217-22. Epub 2004 Nov 6.

PMID:
15538568
32.

Sentinel node biopsy performed before preoperative chemotherapy for axillary lymph node staging in breast cancer.

Schrenk P, Hochreiner G, Fridrik M, Wayand W.

Breast J. 2003 Jul-Aug;9(4):282-7.

PMID:
12846861
33.

Randomised trial: One cycle of anthracycline-containing adjuvant chemotherapy compared with six cycles of CMF treatment in node-positive, hormone receptor-negative breast cancer patients.

Ploner F, Jakesz R, Hausmaninger H, Kolb R, Stierer M, Fridrik M, Steindorfer P, Gnant M, Haider K, Mlineritsch B, Tschurtschenthaler G, Steger G, Seifert M, Kubista E, Samonigg H; Austrian Breast And Colorectal Cancer Study Group.

Onkologie. 2003 Apr;26(2):115-9.

PMID:
12771518
34.

Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6.

Schmid M, Jakesz R, Samonigg H, Kubista E, Gnant M, Menzel C, Seifert M, Haider K, Taucher S, Mlineritsch B, Steindorfer P, Kwasny W, Stierer M, Tausch C, Fridrik M, Wette V, Steger G, Hausmaninger H.

J Clin Oncol. 2003 Mar 15;21(6):984-90.

PMID:
12637461
35.

A randomized study comparing interferon (IFN alpha) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia (CML).

Kühr T, Burgstaller S, Apfelbeck U, Linkesch W, Seewann H, Fridrik M, Michlmayr G, Krieger O, Lutz D, Lin W, Pont J, Köck L, Abbrederis K, Baldinger C, Buder R, Geissler D, Hausmaninger H, Lang A, Zabernigg A, Duba C, Hilbe W, Eisterer W, Fiegl M, Greil R, Gastl G, Thaler J; Austrian CML Study Group.

Leuk Res. 2003 May;27(5):405-11.

PMID:
12620292
36.

Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer--Austrian Breast and Colorectal Cancer Study Group Trial 5.

Jakesz R, Hausmaninger H, Kubista E, Gnant M, Menzel C, Bauernhofer T, Seifert M, Haider K, Mlineritsch B, Steindorfer P, Kwasny W, Fridrik M, Steger G, Wette V, Samonigg H; Austrian Breast and Colorectal Cancer Study Group Trial 5.

J Clin Oncol. 2002 Dec 15;20(24):4621-7.

PMID:
12488405
37.

Dose escalation of ara-c may improve response rates in a subgroup of chronic myeloid leukemia patients with poor response to interferon-alpha and low-dose ara-C.

Hilbe W, Kühr T, Apfelbeck U, Fridrik M, Seewann H, Stöger M, Linkesch W, Pont J, Baldinger C, Hartner E, Bernhart M, Geissler D, Krieger O, Lang A, Lin W, Ludwig H, Duba C, Greil R, Gast G, Thaler J.

Leuk Lymphoma. 2001 Nov-Dec;42(6):1283-8.

PMID:
11911409
38.

[Clinical value of FDG PET using coincident gamma cameras in staging and restaging of malignant lymphoma--compared with convenitonal diagnostic methods].

Pichler R, Maschek W, Hatzl-Griesenhofer M, Huber H, Wimmer G, Wahl G, Fridrik M.

Nuklearmedizin. 2000 Sep;39(6):166-73. German.

PMID:
11057408
39.

Primary gastric B-cell lymphoma: results of a prospective multicenter study. The German-Austrian Gastrointestinal Lymphoma Study Group.

Fischbach W, Dragosics B, Kolve-Goebeler ME, Ohmann C, Greiner A, Yang Q, Böhm S, Verreet P, Horstmann O, Busch M, Dühmke E, Müller-Hermelink HK, Wilms K, Allinger S, Bauer P, Bauer S, Bender A, Brandstätter G, Chott A, Dittrich C, Erhart K, Eysselt D, Ellersdorfer H, Ferlitsch A, Fridrik MA, Gartner A, Hausmaninger M, Hinterberger W, Hügel K, Ilsinger P, Jonaus K, Judmaier G, Karner J, Kerstan E, Knoflach P, Lenz K, Kandutsch A, Lobmeyer M, Michlmeier H, Mach H, Marosi C, Ohlinger W, Oprean H, Pointer H, Pont J, Salabon H, Samec HJ, Ulsperger A, Wimmer A, Wewalka F.

Gastroenterology. 2000 Nov;119(5):1191-202. Erratum in: Gastroenterology 2000 Dec;119(6):1809.

PMID:
11054376
40.

Randomized trial of low-dose chemotherapy added to tamoxifen in patients with receptor-positive and lymph node-positive breast cancer.

Jakesz R, Hausmaninger H, Haider K, Kubista E, Samonigg H, Gnant M, Manfreda D, Tschurtschenthaler G, Kolb R, Stierer M, Fridrik M, Mlineritsch B, Steindorfer P, Mittlböck M, Steger G.

J Clin Oncol. 1999 Jun;17(6):1701-9.

PMID:
10561206
41.

Prognostic significance of mutations in the p53 gene, particularly in the zinc-binding domains, in lymph node- and steroid receptor positive breast cancer patients. Austrian Breast Cancer Study Group.

Kucera E, Speiser P, Gnant M, Szabo L, Samonigg H, Hausmaninger H, Mittlböck M, Fridrik M, Seifert M, Kubista E, Reiner A, Zeillinger R, Jakesz R.

Eur J Cancer. 1999 Mar;35(3):398-405.

PMID:
10448289
42.

Biochemical modulation of 5-fluorouracil by leucovorin with or without interferon-alpha-2c in patients with advanced colorectal cancer: final results of a randomised phase III study.

Hausmaninger H, Moser R, Samonigg H, Mlineritsch B, Schmidt H, Pecherstorfer M, Fridrik M, Kopf C, Nitsche D, Kaider A, Ludwig H.

Eur J Cancer. 1999 Mar;35(3):380-5.

PMID:
10448286
43.

[Therapy studies of the Austrian Breast Cancer Group (ABC)].

Jakesz R, Hausmaninger H, Samonigg H, Kubista E, Haider K, Mlineritsch B, Schmid M, Tausch C, Reiner G, Renner K, Stierer M, Jatzko G, Hofbauer F, Fridrik M, Schennach W, Sevelda P, Dadak C, Haid A, Scholz R, Lenzhofer P, Steindorfer P, Berger A, Mischinger HJ.

Zentralbl Chir. 1998;123 Suppl 5:28-32. German.

PMID:
10063568
44.

Efficacy and toxicity of 2-Chlorodeoxyadenosine (Cladribine)--2 h infusion for 5 days--as first-line treatment for advanced low grade non-Hodgkin's lymphoma.

Fridrik MA, Jäger G, Kienzer HR, Hausmaninger H, Oppitz P, Krieger O, Zabernigg A, Lang A, Neubauer M, Weidinger G, Schiller L, Seewann HL, Chott A, Linkesch W.

Eur J Cancer. 1998 Sep;34(10):1560-4.

PMID:
9893628
45.

Monitoring of remission status by fluorescence in situ hybridisation in chronic myeloid leukaemia patients treated with interferon-alpha.

Duba HC, Peter S, Hilbe W, Fluckinger T, Fridrik M, Erdel M, Thaler J, Utermann G.

Int J Oncol. 1999 Jan;14(1):145-50.

PMID:
9863021
46.

Interferon-alpha for the treatment of elderly patients with chronic myeloid leukaemia.

Hilbe W, Apfelbeck U, Fridrik M, Bernhart M, Niessner H, Abbrederis K, Michlmayr G, Pont J, Linkesch W, Hausmaninger H, Arneitz K, Baldinger C, Duba C, Eisterer W, Greil R, Konwalinka G, Niederwieser D, Gastl G, Thaler J.

Leuk Res. 1998 Oct;22(10):881-6.

PMID:
9766747
47.

Very low-dose adjuvant chemotherapy in steroid receptor negative stage I breast cancer patients. Austrian Breast Cancer Study Group.

Jakesz R, Samonigg H, Gnant M, Kubista E, Steindorfer P, Hausmaninger H, Sevelda P, Tschurtschenthaler B, Fridrik M, Stierer M, Kolb R, Steger G.

Eur J Cancer. 1998 Jan;34(1):66-70.

PMID:
9624239
48.

Chemotherapy in patients with acquired immunodeficiency virus syndrome associated with non-Hodgkin's lymphoma.

Fridrik MA, Geit M, Wahl G, Ehrengruber A, Simma R, Höpfel I, Bettelheim P, Leisch F.

Wien Klin Wochenschr. 1998 Jan 16;110(1):15-9. Review.

PMID:
9499473
49.

Acute renal failure and alendronate.

Zazgornik J, Grafinger P, Biesenbach G, Hubmann R, Fridrik M.

Nephrol Dial Transplant. 1997 Dec;12(12):2797-8. No abstract available.

PMID:
9430905
50.

Randomized open label phase III trial of CEOP/IMVP-Dexa alternating chemotherapy and filgrastim versus CEOP/IMVP-Dexa alternating chemotherapy for aggressive non-Hodgkin's lymphoma (NHL). A multicenter trial by the Austrian Working Group for Medical Tumor Therapy.

Fridrik MA, Greil R, Hausmaninger H, Krieger O, Oppitz P, Stöger M, Klocker J, Neubauer M, Helm W, Pont J, Fazeny B, Hudec M, Simonitsch I, Radaszkiewicz T.

Ann Hematol. 1997 Oct;75(4):135-40. Erratum in: Ann Hematol. 2014 Mar;93(3):539-40.

PMID:
9402845

Supplemental Content

Loading ...
Support Center